Relmada Therapeutics (RLMD) Other Non-Current Assets (2014 - 2026)
Relmada Therapeutics (RLMD) reported Other Non-Current Assets of $19500.0 for Q1 2026, down 11.26% year-over-year from $21975.0 in Q1 2025, and little changed quarter-over-quarter from $19500.0 in Q4 2025.
Relmada Therapeutics (RLMD) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 13 years of Other Non-Current Assets data on file, last reported at $19500.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $19500.0, down 11.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $19500.0 (down 11.26% YoY), and the FY2025 annual result was $19500.0, down 11.26% from the prior year.
- Other Non-Current Assets steadied at $19500.0 in Q1 2026 per RLMD's latest filing, from $19500.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $493452.0 in Q2 2023 and troughed at $2000.0 in Q4 2022.
- A 5-year average of $81891.5 and a median of $21975.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets surged 2965.87% in 2023, then slumped 95.55% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $2000.0 in 2022, then jumped by 2056.25% to $43125.0 in 2023, then tumbled by 49.04% to $21975.0 in 2024, then decreased by 11.26% to $19500.0 in 2025, then changed by 0.0% to $19500.0 in 2026.
- Business Quant data shows RLMD's Other Non-Current Assets at $19500.0 in Q1 2026, $19500.0 in Q4 2025, and $21975.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | 19,500.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,500.00 |
| Dec 31, 2025 | 19,500.00 |
| Sep 30, 2025 | 21,975.00 |
| Jun 30, 2025 | 21,975.00 |
| Mar 31, 2025 | 21,975.00 |
| Dec 31, 2024 | 21,975.00 |
| Sep 30, 2024 | 21,975.00 |
| Jun 30, 2024 | 53,625.00 |
| Mar 31, 2024 | 43,125.00 |
| Dec 31, 2023 | 43,125.00 |
| Sep 30, 2023 | 493,452.00 |
| Jun 30, 2023 | 493,452.00 |
| Mar 31, 2023 | 34,875.00 |
| Dec 31, 2022 | 2,000.00 |
| Sep 30, 2022 | 16,095.00 |
| Jun 30, 2022 | 35,238.00 |
| Mar 31, 2022 | 28,293.00 |
| Dec 31, 2021 | 28,293.00 |
| Sep 30, 2021 | 25,000.00 |
| Jun 30, 2021 | 25,000.00 |